ERBB2 and breast cancer: Our results showed that the degree of changes in LVEF and cardiac injury biomarkers were not different between groups, while the increases in LF/HF ratio and cellular oxidative stress in peripheral blood mononuclear cells were significantly greater in HER2-negative than that of HER2-positive breast cancer patients (Additional file 1: Fig. S2).